Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
about
Epigenetic polypharmacology: from combination therapy to multitargeted drugsBifunctional Conjugates with Potent Inhibitory Activity Towards Cyclooxygenase and Histone DeacetylaseTargeting Non-Catalytic Cysteine Residues Through Structure-Guided Drug DiscoveryA facile route to form self-carried redox-responsive vorinostat nanodrug for effective solid tumor therapyCatalytic Metallodrugs: Substrate-Selective Metal Catalysts as Therapeutics.Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors.
P2860
Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
@ast
Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
@en
type
label
Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
@ast
Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
@en
prefLabel
Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
@ast
Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
@en
P2093
P2860
P1476
Dual-Mode HDAC Prodrug for Covalent Modification and Subsequent Inhibitor Release.
@en
P2093
Carol A Fierke
Eric D Sullivan
Joshua C Chan
Kevin B Daniel
Patricia A Jennings
P2860
P304
P356
10.1021/ACS.JMEDCHEM.5B00539
P407
P577
2015-06-02T00:00:00Z